RECOVER-TLC July 2026 Update: Long COVID Clinical Trial Progress
July 16, 2026
The National Institutes of Health (NIH) hosted a community webinar on July 16, 2026, to provide updates on the RECOVER-Treating Long COVID (RECOVER-TLC) initiative. NIH leaders emphasized that Long COVID research and treatment development remain priorities across NIAID and NIH before researchers reviewed four clinical trials underway or in development, discussed how biomarkers will be incorporated into the studies, explained the clinical trial development process, and answered questions from the Long COVID community.
RECOVER-TLC Moves From Planning to Clinical Trials
The webinar opened by acknowledging the frustration many people living with Long COVID have expressed over the pace of therapeutic research. Investigators emphasized that although no treatment has yet been proven effective, the RECOVER-TLC program has now reached an important transition point.
Originally envisioned in late 2024, RECOVER-TLC was created to rapidly evaluate both pharmacologic and non-pharmacologic therapies for Long COVID while remaining guided by emerging science and ongoing community input. Researchers said the program continues to build on findings from the larger RECOVER observational studies, evolving pathobiology research, and recommendations from scientific experts, industry partners, and people with lived experience.
Four Long COVID Treatment Trials Continue to Advance
Researchers then provided updates on the four therapeutic interventions currently included in the RECOVER-TLC portfolio.
The Reverse LC trial evaluating baricitinib is actively enrolling participants. As of early July 2026, the study had enrolled 279 participants toward its goal of 550, with enrollment expected to accelerate as additional study sites become active.
The Brave LC trial evaluating low-dose naltrexone (LDN) has completed protocol development and is currently undergoing regulatory review. Investigators expect the study to begin enrolling participants in late September or early October 2026, assuming manufacturing proceeds as planned.
The Tame LC trial evaluating semaglutide, a GLP-1 receptor agonist, is also progressing. The protocol has been updated following public comment and collaboration with Novo Nordisk, and researchers anticipate enrollment will begin in late fall 2026 while study site selection continues across the United States.
The fourth study, Block LC, will evaluate stellate ganglion nerve block and is advancing through protocol development and site selection. Investigators said its enrollment timeline is expected to be similar to the semaglutide trial, with recruitment potentially beginning in the fall or late fall of 2026, although the schedule may change as regulatory and site preparation work continues.
Long COVID Biomarkers Could Help Explain Why Treatments Work
Investigators also discussed how biomarkers will be incorporated into each trial.
Although researchers have identified several promising biological signals associated with Long COVID, they noted that there is still no consensus on a reliable biomarker for the condition. To develop the core biomarker panel, the team reviewed the scientific literature and prioritized biomarkers that had shown differences between people with Long COVID and comparison groups in at least two published studies. These core biomarkers will be collected across all RECOVER-TLC trials, while additional trial-specific panels will explore how individual treatments affect different biological pathways. The biomarkers are exploratory and are not being used as established diagnostic tests.
Researchers hope these measurements will help show whether biological changes correspond with improvements in symptoms, patient-reported outcomes, and objective measures such as grip strength and active stand testing.
Why Do Long COVID Clinical Trials Take So Long?
One of the webinar’s most detailed discussions focused on why launching national clinical trials requires substantial time before participants can be enrolled.
Researchers explained that developing a clinical trial involves far more than selecting a promising treatment. Each study requires extensive protocol development, statistical planning, participant safety monitoring, FDA review, Institutional Review Board approval, site selection, staff training, standardized data collection systems, and manufacturing of study medications when needed.
The team highlighted low-dose naltrexone as an example. Because LDN is commonly prepared by compounding pharmacies rather than manufactured as a standardized commercial product, researchers have needed to develop a uniform formulation that is stable, consistent, and free of impurities before it can be used in a national clinical trial. They noted that this manufacturing process has taken longer than anticipated but is essential to ensuring participant safety and producing reliable scientific results.
Investigators also emphasized that community participation has shaped every stage of protocol development. People living with Long COVID have contributed through protocol review groups, therapeutic evaluation panels, and a newly established community advisory board, helping ensure the studies address meaningful patient priorities while remaining scientifically rigorous.
Community Questions
During the question-and-answer session, researchers addressed questions about eligibility, enrollment timelines, biomarkers, and future therapeutic development.
Investigators said people who developed Long COVID after infections during the first wave of the pandemic in 2020 may still be eligible. The length of time a person has been ill does not automatically exclude them, but participants must meet the program’s definition of Long COVID, including at least three months of symptoms, as well as the specific eligibility requirements for the individual trial.
Investigators also reiterated that the RECOVER-TLC therapeutic submission portal remains open. 625 treatment proposals have already been submitted by nearly 400 individuals, and new interventions will continue to be reviewed as additional scientific evidence emerges.
What Comes Next for RECOVER-TLC
While investigators acknowledged that many people are eager for effective Long COVID treatments, they emphasized that carefully designed clinical trials remain the fastest path toward identifying therapies that are both safe and effective.
With enrollment already underway for one study and several additional trials expected to begin recruiting this fall, RECOVER-TLC is entering a new phase focused on evaluating potential treatments including baricitinib, low-dose naltrexone, semaglutide, and stellate ganglion nerve block. Results from these studies may help guide future Long COVID treatment strategies while advancing understanding of the condition’s underlying biology.
Additional RECOVER-TLC updates are expected through an August newsletter, another community webinar planned for September, and the initiative’s third annual workshop on November 4 and 5, 2026.
Citation
National Institute of Allergy and Infectious Diseases (NIAID) and Foundation for the National Institutes of Health (FNIH). RECOVER-TLC: Long COVID Clinical Trials Update. Community webinar. July 16, 2026. Available at: https://youtu.be/zNFFfDbMfpc?si=SHpXJry86k1e3fNw